Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results [Financial Post (Toronto, Ontario, Canada)]
Edesa Biotech, Inc. - Common Shares (EDSA)
Company Research
Source: Financial Post
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business. During the quarter, the company's anti-TLR4 drug candidate, EB05 (paridiprubart), was selected by the U.S. Department of Health and Human Services for use in a U.S. government-funded platform study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Edesa is providing drug product for the trial as well as technical support at its own expense. In addition, the company reported today that it plans to continue utilizing its internal resources to advance its vitiligo and pulmonary fibrosis programs, including preparations to file an Investigational New Drug application with the U.S. Food and Dru
Show less
Read more
Impact Snapshot
Event Time:
EDSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDSA alerts
High impacting Edesa Biotech, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
EDSA
News
- Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech, Inc. (NASDAQ: EDSA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results [Yahoo! Finance]Yahoo! Finance
EDSA
Analyst Actions
- 8/20/24 - HC Wainwright
EDSA
Sec Filings
- 9/3/24 - Form 4
- 8/9/24 - Form 10-Q
- 8/9/24 - Form 8-K
- EDSA's page on the SEC website